Northwest Biotherapeutics, Inc. (NWBO)
0.1537
0.00 (0.00%)
USD |
OTCM |
Oct 02, 16:00
Northwest Biotherapeutics Enterprise Value : 329.47M for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 329.47M |
| October 01, 2026 | 327.30M |
| September 30, 2026 | 321.46M |
| September 29, 2026 | 322.46M |
| September 28, 2026 | 327.47M |
| September 25, 2026 | 339.99M |
| September 24, 2026 | 339.32M |
| September 23, 2026 | 339.40M |
| September 22, 2026 | 344.99M |
| September 21, 2026 | 351.67M |
| September 18, 2026 | 340.15M |
| September 17, 2026 | 349.17M |
| September 16, 2026 | 349.32M |
| September 15, 2026 | 360.19M |
| September 14, 2026 | 348.00M |
| September 11, 2026 | 354.84M |
| September 10, 2026 | 348.75M |
| September 09, 2026 | 355.71M |
| September 08, 2026 | 355.60M |
| September 04, 2026 | 356.10M |
| September 03, 2026 | 356.53M |
| September 02, 2026 | 355.68M |
| September 01, 2026 | 353.34M |
| August 31, 2026 | 356.97M |
| August 28, 2026 | 389.40M |
| Date | Value |
|---|---|
| August 27, 2026 | 371.94M |
| August 26, 2026 | 361.69M |
| August 25, 2026 | 363.19M |
| August 24, 2026 | 360.82M |
| August 21, 2026 | 356.01M |
| August 20, 2026 | 358.78M |
| August 19, 2026 | 369.28M |
| August 18, 2026 | 373.21M |
| August 17, 2026 | 377.55M |
| August 14, 2026 | 393.40M |
| August 13, 2026 | 390.07M |
| August 12, 2026 | 388.06M |
| August 11, 2026 | 390.07M |
| August 10, 2026 | 383.39M |
| August 07, 2026 | 379.38M |
| August 06, 2026 | 370.87M |
| August 05, 2026 | 346.66M |
| August 04, 2026 | 341.66M |
| August 03, 2026 | 339.15M |
| July 31, 2026 | 346.66M |
| July 30, 2026 | 348.33M |
| July 29, 2026 | 343.33M |
| July 28, 2026 | 359.00M |
| July 27, 2026 | 362.68M |
| July 24, 2026 | 359.48M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.551B |
| Alnylam Pharmaceuticals, Inc. | 29.06B |
| Savara, Inc. | 845.34M |
| Vericel Corp. | 1.987B |
| Biogen, Inc. | 39.55B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -9.221M |
| Revenue (Quarterly) | 0.807M |
| Total Expenses (Quarterly) | 10.03M |
| EPS Diluted (Quarterly) | -0.0058 |
| Gross Profit Margin (Quarterly) | -5.58% |
| Profit Margin (Quarterly) | -1.14K% |
| Earnings Yield | -16.53% |
| Normalized Earnings Yield | -23.16 |